A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab

This study has been completed.

Sponsor:

Collaborator:

Novartis Pharmaceuticals

Information provided by (Responsible Party):

John C. Fang, M.D., University of Utah

ClinicalTrials.gov Identifier:

NCT00123630

First received: July 21, 2005

Last updated: August 9, 2013

Last verified: August 2013

History of Changes

Results First Received: September 5, 2012

Study Type:	Interventional
Study Design:	Allocation: Randomized; Endpoint Classification: Safety/Efficacy Study; Intervention Model: Parallel Assignment; Masking: Double Blind (Subject, Caregiver, Investigator); Primary Purpose: Treatment
Condition:	Esophagitis
Interventions:	Drug: omalizumab Drug: Placebo

Participant Flow

Show Participant Flow

Baseline Characteristics

Hide Baseline Characteristics

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups

	Description
Placebo	Placebo 150 to 375 mg is administered SC every 2 or 4 weeks. Because the solution is slightly viscous, the injection may take 5-10 seconds to administer. Doses (mg) and dosing frequency are determined by serum total IgE level (IU/mL), measured before the start of treatment, and body weight (kg).
Omalizumab	Xolair (Omalizumab)150 to 375 mg is administered SC every 2 or 4 weeks. Because the solution is slightly viscous, the injection may take 5-10 seconds to administer. Doses (mg) and dosing frequency are determined by serum total IgE level (IU/mL), measured before the start of treatment, and body weight (kg).
Total	Total of all reporting groups

Baseline Measures

	Placebo	Omalizumab	Total
Number of Participants [units: participants]	15	15	30
Age [units: participants]
<=18 years	0	0	0
Between 18 and 65 years	15	15	30
>=65 years	0	0	0
Age [units: years] Mean ± Standard Deviation	28 ± 6	32 ± 12	30 ± 10
Gender [units: participants]
Female	5	3	8
Male	10	12	22
Region of Enrollment [units: participants]
United States	15	15	30

Outcome Measures

1. Primary:

Change in Eosinophil Numbers Per High Power Field Proximally and Distally Between Baseline and Post-treatment and Between Both Groups [ Time Frame: 16 weeks ]

Show Outcome Measure 1

2. Secondary:

To Determine the Effect of Omalizumab on Other Clinical and Histological Parameters of EE Including Reducing the Symptoms of EE Measured by Overall Improvement in Esophageal Symptoms [ Time Frame: 16 weeks ]

Results not yet reported. Anticipated Reporting Date: No text entered. Safety Issue: No

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

Limitations and Caveats

Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
small numbers enrolled

More Information

Show More Information

To Top